ArticleIJTLD open2026
Quality of life outcomes and patient-reported experiences in a randomised controlled trial for rifampicin-resistant TB (PRACTECAL-PRO): a mixed-methods study.
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe TB-PRACTECAL clinical trial assessed 24-week, all-oral bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant TB against standard of care (SoC). The PRACTECAL-PRO sub-study evaluated changes in quality of life (QoL), among patients receiving investigational regimens versus SoC, and assessed patient experiences of the new treatments.
methodsWe recruited participants from Belarus, Uzbekistan, and South Africa. Changes in QoL from baseline to 48 weeks were evaluated using the Short Form-12 (SF-12) and the St George's Respiratory Questionnaire (SGRQ). Longitudinal analysis was conducted for all six domains of SF-12 and SGRQ. In-depth interviews provided narratives about patients' experiences.
results137 patients participated in PRACTICAL-PRO. All trial arms showed improved SF-12 and SGRQ scores over 48 weeks. Proportional reduction in scores for SGRQ per month was higher in investigational than SoC groups' Total score (13% vs. 4%), Impact (12% vs. 2%), Activity (14% vs. 7%), and Symptom (15% vs. 4%) domains, indicating quicker QoL improvement. Narratives indicated early treatment satisfaction and social acceptance, with wellbeing relying on family support, clinical contact, and counselling.
conclusionPatients receiving short, all-oral BPaL-based regimens show improvements across all measured QoL domains, a positive impact on personal relationships, and a return to productive life. TB trials should routinely include patient-reported outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.